FR2853650B1 - Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance - Google Patents

Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Info

Publication number
FR2853650B1
FR2853650B1 FR0304486A FR0304486A FR2853650B1 FR 2853650 B1 FR2853650 B1 FR 2853650B1 FR 0304486 A FR0304486 A FR 0304486A FR 0304486 A FR0304486 A FR 0304486A FR 2853650 B1 FR2853650 B1 FR 2853650B1
Authority
FR
France
Prior art keywords
dedoubling
insulino
amine
treatment
disorders associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0304486A
Other languages
English (en)
Other versions
FR2853650A1 (fr
Inventor
Gerard Moinet
Daniel Cravo
Thierry Passemar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0304486A priority Critical patent/FR2853650B1/fr
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Priority to CA2521879A priority patent/CA2521879C/fr
Priority to DE602004019897T priority patent/DE602004019897D1/de
Priority to ES04725892T priority patent/ES2321718T3/es
Priority to PL377833A priority patent/PL214955B1/pl
Priority to DK04725892T priority patent/DK1611111T3/da
Priority to US10/551,956 priority patent/US7501511B2/en
Priority to JP2006504628A priority patent/JP4836778B2/ja
Priority to PCT/EP2004/002476 priority patent/WO2004089917A2/fr
Priority to PT04725892T priority patent/PT1611111E/pt
Priority to SI200431141T priority patent/SI1611111T1/sl
Priority to AT04725892T priority patent/ATE425151T1/de
Priority to EP04725892A priority patent/EP1611111B1/fr
Priority to RU2005134685/04A priority patent/RU2344131C2/ru
Priority to AU2004228125A priority patent/AU2004228125B2/en
Priority to KR1020057019154A priority patent/KR101107665B1/ko
Priority to MXPA05010764A priority patent/MXPA05010764A/es
Priority to CNB2004800096564A priority patent/CN100383130C/zh
Priority to BRPI0409258A priority patent/BRPI0409258B8/pt
Priority to TW093109613A priority patent/TWI344464B/zh
Priority to ARP040101178A priority patent/AR044511A1/es
Publication of FR2853650A1 publication Critical patent/FR2853650A1/fr
Priority to ZA200509071A priority patent/ZA200509071B/en
Publication of FR2853650B1 publication Critical patent/FR2853650B1/fr
Application granted granted Critical
Priority to HK06108146A priority patent/HK1088002A1/xx
Priority to CY20091100572T priority patent/CY1109609T1/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR0304486A 2003-04-10 2003-04-10 Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance Expired - Fee Related FR2853650B1 (fr)

Priority Applications (24)

Application Number Priority Date Filing Date Title
FR0304486A FR2853650B1 (fr) 2003-04-10 2003-04-10 Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
AU2004228125A AU2004228125B2 (en) 2003-04-10 2004-04-06 Process for resolving 2,4-diamino-3,6-dihydro-1,3,5-triazines, useful for the treatment of disorders associated with insulin resistance syndrome
ES04725892T ES2321718T3 (es) 2003-04-10 2004-04-06 Procedimiento para la resolucion de 2,4-diamino-3,6-dihidrido-1,3,5-triazinas, utiles para el tratamiento de desordenes asociados con el sindrome de resistencia a la insulina.
PL377833A PL214955B1 (pl) 2003-04-10 2004-04-06 Sposób rozdzielania amin przydatnych do leczenia zaburzen zwiazanych z zespolem opornosci insulinowej
DK04725892T DK1611111T3 (da) 2003-04-10 2004-04-06 Fremgangsmåde til resolvering af 2,4-diamino-3,6-dihydro-1,3,5-triaziner der er egnede til behandling af lidelser som er forbundet med insulinresistenssyndrom
US10/551,956 US7501511B2 (en) 2003-04-10 2004-04-06 Process for resolving aimines that are useful for the treatment of disorders associated with insulin resistance syndrome
JP2006504628A JP4836778B2 (ja) 2003-04-10 2004-04-06 インスリン抵抗性症候群に関連する疾患の治療に有用なアミンを分割するための方法
PCT/EP2004/002476 WO2004089917A2 (fr) 2003-04-10 2004-04-06 Procede de dedoublement permettant d'obtenir des amines utiles pour le traitement des troubles associes au syndrome de d'insulino-resistance
PT04725892T PT1611111E (pt) 2003-04-10 2004-04-06 Processo para resolução de aminas que são uteis no tratamento de patologias associadas à síndrome de resistência à insulina
DE602004019897T DE602004019897D1 (de) 2003-04-10 2004-04-06 Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung vkrankungen eignen
AT04725892T ATE425151T1 (de) 2003-04-10 2004-04-06 Verfahren zur racematspaltung von 2,4-diamino-3,6-dihydro-1,3,5-triazinen, die sich zur behandlung von mit dem insulinresistenzsyndrom assoziierten erkrankungen eignen
EP04725892A EP1611111B1 (fr) 2003-04-10 2004-04-06 Procede de dedoublement permettant d'obtenir des amines utiles pour le traitement des troubles associes au syndrome de d'insulino-resistance
CA2521879A CA2521879C (fr) 2003-04-10 2004-04-06 Processus permettant de resoudre des amines utiles pour le traitement d'affections associees au syndrome d'insulinoresistance
RU2005134685/04A RU2344131C2 (ru) 2003-04-10 2004-04-06 Способ разделения аминов, которые являются полезными для лечения расстройств, ассоциированных с синдромом инсулинрезистентности
SI200431141T SI1611111T1 (sl) 2003-04-10 2004-04-06 Postopek raztapljanja 2,4-diamino-3,6-dihidro-1,3,5-triazinov, uporabnih za zdravljenje motenj, povezanih s sindromom inzulinske rezistence
MXPA05010764A MXPA05010764A (es) 2003-04-10 2004-04-06 Procedimiento para resolver aminas que son utiles para el tratamiento de trastornos asociados con el sindrome de resistencia a la insulina.
CNB2004800096564A CN100383130C (zh) 2003-04-10 2004-04-06 可用于治疗胰岛素耐受综合征相关病症的2,4-二氨基-3,6-二氢-1,3,5-三嗪类化合物的拆分方法
BRPI0409258A BRPI0409258B8 (pt) 2003-04-10 2004-04-06 processo para resolução de compostos racêmicos
KR1020057019154A KR101107665B1 (ko) 2003-04-10 2004-04-06 인슐린 내성 증후군 관련 장애의 치료에 유용한,２,４-디아미노-３,６-디하이드로-１,３,５-트리아진의분리 방법
TW093109613A TWI344464B (en) 2003-04-10 2004-04-07 Process for resolving amines that are useful for the treatment of disorders associated with insulin resistnace syndrome
ARP040101178A AR044511A1 (es) 2003-04-10 2004-04-07 Procedimiento para resolver triazinas utilizadas en el tratamiento de sindrome de resistencia a la insulina
ZA200509071A ZA200509071B (en) 2003-04-10 2005-11-09 Process for resolving 2,4-diamino-3,6-dihydro-1,3,5-triazines, useful for the treatment of disorders associated with insulin resistance syndrome
HK06108146A HK1088002A1 (en) 2003-04-10 2006-07-21 Process for resolving 2,4-diamino-3,6-dihydro-1,3,5-triazines, useful for the treatment of disordersassociated with insulin resistance syndrome
CY20091100572T CY1109609T1 (el) 2003-04-10 2009-05-28 Μεθοδος για διαχωρισμο 2,4-διαμινο-3,6-διυδρο-1,3,5-τριαζινων, χρησιμων για τη θεραπεια διαταραχων που συνδεονται με το συνδρομο ανθεκτικοτητας στην ινσουλινη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0304486A FR2853650B1 (fr) 2003-04-10 2003-04-10 Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Publications (2)

Publication Number Publication Date
FR2853650A1 FR2853650A1 (fr) 2004-10-15
FR2853650B1 true FR2853650B1 (fr) 2006-07-07

Family

ID=33041769

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0304486A Expired - Fee Related FR2853650B1 (fr) 2003-04-10 2003-04-10 Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Country Status (24)

Country Link
US (1) US7501511B2 (fr)
EP (1) EP1611111B1 (fr)
JP (1) JP4836778B2 (fr)
KR (1) KR101107665B1 (fr)
CN (1) CN100383130C (fr)
AR (1) AR044511A1 (fr)
AT (1) ATE425151T1 (fr)
AU (1) AU2004228125B2 (fr)
BR (1) BRPI0409258B8 (fr)
CA (1) CA2521879C (fr)
CY (1) CY1109609T1 (fr)
DE (1) DE602004019897D1 (fr)
DK (1) DK1611111T3 (fr)
ES (1) ES2321718T3 (fr)
FR (1) FR2853650B1 (fr)
HK (1) HK1088002A1 (fr)
MX (1) MXPA05010764A (fr)
PL (1) PL214955B1 (fr)
PT (1) PT1611111E (fr)
RU (1) RU2344131C2 (fr)
SI (1) SI1611111T1 (fr)
TW (1) TWI344464B (fr)
WO (1) WO2004089917A2 (fr)
ZA (1) ZA200509071B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896161B1 (fr) * 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
CN101468986B (zh) * 2007-12-26 2010-12-29 香港南北兄弟国际投资有限公司 一种二氢嘧啶消旋化合物的拆分方法
DE102008007314A1 (de) * 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
EA018921B1 (ru) * 2008-05-23 2013-11-29 Поксел Сас Способ синтеза производных 3,6-дигидро-1,3,5-триазина
WO2010012746A2 (fr) * 2008-07-29 2010-02-04 Poxel Procédé permettant, dans des mélanges d'énantiomères, d'extraire des énantiomères par cristallisation à contrôle des calibres particulaires
DE102009014898A1 (de) * 2009-03-25 2010-09-30 Merck Patent Gmbh Prozess zur Enantiomerentrennung von 3,6-Dihydro-1,3,5-triazinderivaten
ES2436633T3 (es) * 2009-03-26 2014-01-03 Poxel Procedimiento para la separación de enantiómeros de dihidro-1,3,5-triazinas racémicas por cristalización preferencial
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
WO2011154496A1 (fr) 2010-06-09 2011-12-15 Poxel Traitement du diabète de type 1
TWI428311B (zh) * 2010-12-01 2014-03-01 Poxel 使用酒石酸分離三衍生物鏡像異構物
BR112020006472A2 (pt) 2017-10-02 2020-10-06 Poxel método para tratamento ou prevenção de insuficiência cardíaca com fração de ejeção preservada (icfep)
WO2019236844A1 (fr) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Méthodes de traitement de sujets atteints de diabète avec une maladie rénale chronique
MX2020013567A (es) 2018-06-14 2021-05-27 Poxel Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes.
WO2022152138A1 (fr) * 2021-01-15 2022-07-21 中国医药研究开发中心有限公司 Composé hétérocyclique condensé, son procédé de préparation et son utilisation médicale

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894027A (en) * 1973-07-31 1975-07-08 Merck & Co Inc Resolution of racemic reticuline and racemization of its enantiomers
JPS5414986A (en) * 1977-07-01 1979-02-03 Taiho Pharmaceutical Co Ltd Production of dihydrooss triazine derivative
JPH0436279A (ja) * 1990-06-01 1992-02-06 Kyowa Hakko Kogyo Co Ltd 光学活性なベンゾオキセピン誘導体の製造法
FR2665441B1 (fr) * 1990-07-31 1992-12-04 Sanofi Sa Derives de la n-sulfonyl indoline, leur preparation, les compositions pharmaceutiques en contenant.
EP0974592A4 (fr) * 1995-09-22 2001-09-19 Fujisawa Pharmaceutical Co Nouveaux procedes de production de derives de pyridoindole
MX9805870A (fr) * 1996-01-22 1999-01-31
JPH11193270A (ja) * 1997-12-26 1999-07-21 Koei Chem Co Ltd 光学活性１−メチル−３−ピペリジンメタノールの製造方法
JP4138928B2 (ja) * 1998-02-20 2008-08-27 山川薬品工業株式会社 Ｄ−アロイソロイシンの製造方法および製造の中間体
FR2775974B1 (fr) * 1998-03-16 2000-08-18 Rhodia Chimie Sa Procede de separation de diastereoisomeres d'une diphosphine et preparation de diphosphines optiquement actives
WO2000000479A1 (fr) * 1998-06-30 2000-01-06 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones et 1,3-benzoxazepin-2-ones utilisees comme inhibiteurs de la reverse-transcriptase du vih
JP2001199972A (ja) * 2000-01-20 2001-07-24 Eisai Co Ltd 光学活性ピペラジン誘導体の製造法
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
JP2002193933A (ja) * 2000-06-14 2002-07-10 Toray Ind Inc 光学活性ピペリジン誘導体またはその酸塩の製造方法
DE10042064A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10125131A1 (de) * 2001-05-23 2002-12-05 Bayer Ag Verfahren zur Spaltung des Methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrmidincarboxylat-Racemats
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram

Also Published As

Publication number Publication date
RU2344131C2 (ru) 2009-01-20
JP4836778B2 (ja) 2011-12-14
SI1611111T1 (sl) 2009-08-31
TW200504037A (en) 2005-02-01
AU2004228125A1 (en) 2004-10-21
MXPA05010764A (es) 2005-12-12
ATE425151T1 (de) 2009-03-15
ES2321718T3 (es) 2009-06-10
BRPI0409258B8 (pt) 2021-05-25
EP1611111B1 (fr) 2009-03-11
KR101107665B1 (ko) 2012-01-20
DK1611111T3 (da) 2009-05-18
AR044511A1 (es) 2005-09-14
KR20050120791A (ko) 2005-12-23
CN100383130C (zh) 2008-04-23
HK1088002A1 (en) 2006-10-27
WO2004089917A2 (fr) 2004-10-21
WO2004089917A3 (fr) 2004-12-23
DE602004019897D1 (de) 2009-04-23
BRPI0409258B1 (pt) 2018-05-15
RU2005134685A (ru) 2006-06-10
JP2006522753A (ja) 2006-10-05
CN1771233A (zh) 2006-05-10
CA2521879C (fr) 2013-01-08
US20060223803A1 (en) 2006-10-05
PL377833A1 (pl) 2006-02-20
AU2004228125B2 (en) 2010-07-15
US7501511B2 (en) 2009-03-10
EP1611111A2 (fr) 2006-01-04
TWI344464B (en) 2011-07-01
ZA200509071B (en) 2007-04-25
CA2521879A1 (fr) 2004-10-21
PL214955B1 (pl) 2013-10-31
CY1109609T1 (el) 2014-08-13
PT1611111E (pt) 2009-06-18
BRPI0409258A (pt) 2006-03-28
FR2853650A1 (fr) 2004-10-15

Similar Documents

Publication Publication Date Title
FR2853650B1 (fr) Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
FR2868414B1 (fr) Procede de production d'alpha-alumine particulaire et apha-alumine particulaire produite par ce procede
NO20014047D0 (no) Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser
CY2015025I1 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
MA28791B1 (fr) Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
MA28555B1 (fr) Derives de morpholine substitues pour le traitement de troubles du systeme nerveux central
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
NO20043237L (no) Dihydrobenzodiazepin-2-onderivater for behandling av neurologiske forstyrrelser
NO20035610L (no) Fremgangsmate for behandling av vaeskeformig hydrokarbon
DK1202986T3 (da) Amin- og amidderivater som ligander for neuropeptid Y-Y5-receptoren, der er nyttige ved behandlingen af obesitet og andre lidelser
DE60309909D1 (de) Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
ID30276A (id) Metode untuk mengobati gangguan-gangguan seksual
FR2842200B1 (fr) Procede pour l'obtention de polysaccharides modifies
FR2884715B1 (fr) Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
FR13C0044I2 (fr) Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
FR2834984B1 (fr) Procede continu d'hydrogenation de nitriles ou composes nitres en amines
FR2869030B1 (fr) Procede de production d'alpha-alumine particulaire
ITMI20052320A1 (it) Dispositivo di regolazione dell'altezza di selle o manubri
FR2846977B1 (fr) Procede pour ameliorer la qualite de non tisses
MA26075A1 (fr) Procede pour le traitement d'huile usagee.
FR2826364B1 (fr) Procede d'hemihydrogenation de dinitriles en aminonitriles
ATE345818T1 (de) S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.
MA28513B1 (fr) Processus pour la preparation d'inhibiteurs de tryptase

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

ST Notification of lapse

Effective date: 20211205